Lymphocyte Count as a Predictor of Adjuvant Chemotherapy Completion After Severe Postoperative Com

Background and Study Aim

The PubMed record for this multicenter study states that postoperative complications can disrupt the continuation and completion of adjuvant chemotherapy (ACT) in patients with stage III colorectal cancer. The reported aim is to identify a simple indicator that can predict whether patients with severe postoperative complications will complete ACT. The title identifies lymphocyte count as the candidate predictor under investigation.

Authorship and Publication Details

The study is authored by Takuki Yagyu et al. and is published in Anticancer Research (2026 Sep;46(9):5055-5065). The work lists multiple coauthors affiliated primarily with the Division of Gastrointestinal and Pediatric Surgery, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University, Yonago, Japan, and with several regional hospitals in Tottori Prefecture and surrounding areas. The PubMed identifier is PMID 42674714 and the DOI is 10.21873/anticanres.18354.

Available Abstract Excerpt

The only substantive sentence from the abstract in the accessible PubMed record reads: “Postoperative complications can interfere with the continuation and completion of adjuvant chemotherapy (ACT) in stage III colorectal cancer. However, simple indicators for predicting treatment completion after severe postoperative c” — the text is truncated in the source. From this fragment we can confirm the study's clinical problem (ACT interruption after complications) and the stated objective (to find a simple predictive indicator), and that lymphocyte count is the feature emphasized in the article title.

Missing Data and Unreported Details in Source

The PubMed entry provided here is incomplete. The following core study elements were not reported in the accessible source text and therefore cannot be summarized from this record:

• Study design specifics (prospective vs retrospective), inclusion/exclusion criteria, and number of participating centers beyond the multicenter designation.
• Patient population details (sample size, stage distribution, demographics, baseline comorbidities).
• Definitions used for “severe postoperative complications” and timing of complication assessment.
• How lymphocyte count was measured (absolute count, timing relative to surgery/complication, cutoff values) and whether other immune or laboratory markers were evaluated.
• Details of adjuvant chemotherapy regimens, schedules, reasons for discontinuation, and criteria for completion.
• Statistical methods, adjustments for confounders, and any subgroup analyses.
• Primary and secondary outcomes, numerical results, effect sizes, confidence intervals, p-values, and explicit author conclusions.

Because these elements are not present in the provided PubMed content, no outcome statements, predictive thresholds, or clinical recommendations can be extracted or reported from this source alone.

Clinical and Research Implications (Based on Article Topic as Reported)

The article addresses an important clinical question: whether a routinely measurable laboratory parameter—lymphocyte count—can predict which patients will be able to complete adjuvant chemotherapy after experiencing severe postoperative complications. If validated and reproducible, such an indicator could have multiple uses, including:

• Risk stratification of patients recovering from colorectal surgery who require ACT.
• Informing shared decision-making about the timing of chemotherapy initiation after complications.
• Guiding intensified supportive care or immunonutrition for patients at high risk of ACT discontinuation.

However, the actual evidence, operational definitions, and statistical robustness of any predictive relationship are not available in the truncated PubMed entry. Therefore, these implications are conceptual and cannot be taken as findings or recommendations from this specific study without consulting the full article.

How to Access Full Study

The truncated PubMed abstract limits the ability to appraise the study. To review methods, results, and authors' conclusions, retrieve the full text via one of the following routes:

• Use the DOI link (10.21873/anticanres.18354) to access the article on the journal publisher’s site or through an institutional subscription.
• Access Anticancer Research volume 46, issue 9 (2026 Sep), pages 5055–5065, via a library or database that provides the journal.
• Contact corresponding author(s) listed in the PubMed record for supplementary information or to request a copy if institutional access is not available.

Summary

This multicenter report, titled "Lymphocyte Count Predicts Adjuvant Chemotherapy Completion After Severe Postoperative Complications in Colorectal Cancer," proposes lymphocyte count as a potential simple predictor for completing ACT after major postoperative complications. The PubMed entry is truncated and lacks critical methodological and results data; therefore, no study-specific outcomes or clinical recommendations can be accurately reported from this source alone. Clinicians and researchers should consult the full published article for complete information before applying any findings to practice.